Stock YP1A IMMUTEP ADR
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Delayed Deutsche Boerse AG
Other stock markets
 02:16:58 2024-06-03 EDT 		5-day change 1st Jan Change
2.66 EUR +3.91% Intraday chart for Immutep ADR +3.10% +25.47%
10:57am Immutep, Merck Collaborate on Trial for Lung Cancer Therapy MT
07:20am Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial MT

Evolution of the average Target Price on Immutep ADR

Price target over the last 5 years

History of analyst recommendation changes

fb686dadd325795f.zyw2yjjDeZ5mNWtYlEyArCzCKfT7VcPChJWb5kbFReM.nxtpq2CwNfgAeBwZxHrGlW-JXKuCHLeq1OPV1wiGM9v-e1iEaKkD0AdDWw~838ff95fd81aacee44a1dec7aaedca36

Analyst Recommendations on Immutep ADR

Capital One Initiates Immutep at Overweight Rating With $10 Price Target MT
Canaccord Starts Immutep at Buy, Price Target is AU$1.00 MT
Baird Initiates Immutep With Outperform Rating, $7 Price Target MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
Immutep : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target PU
IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target MT
Immutep : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 PT PU
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.45 AUD
Average target price
0.978 AUD
Spread / Average Target
+117.33%
High Price Target
1.1 AUD
Spread / Highest target
+144.44%
Low Price Target
0.8 AUD
Spread / Lowest Target
+77.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immutep ADR

Capital One Securities
Canaccord Genuity
Baird
Maxim
Ladenburg Thalmann

Ratings for Immutep ADR

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IMM Stock
  4. YP1A Stock
  5. Consensus Immutep ADR